$3.75 Million in Sales Expected for Wave Life Sciences Ltd. (NASDAQ:WVE) This Quarter

Brokerages expect that Wave Life Sciences Ltd. (NASDAQ:WVEGet Rating) will report sales of $3.75 million for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Wave Life Sciences’ earnings, with the lowest sales estimate coming in at $2.00 million and the highest estimate coming in at $5.50 million. The company is expected to issue its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Wave Life Sciences will report full-year sales of $15.00 million for the current fiscal year, with estimates ranging from $8.00 million to $22.00 million. For the next year, analysts forecast that the firm will post sales of $17.33 million, with estimates ranging from $8.00 million to $31.64 million. Zacks’ sales calculations are an average based on a survey of analysts that follow Wave Life Sciences.

Wave Life Sciences (NASDAQ:WVEGet Rating) last announced its quarterly earnings results on Thursday, March 3rd. The company reported ($0.61) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.14). The company had revenue of $1.77 million for the quarter, compared to analysts’ expectations of $18.14 million. During the same quarter in the prior year, the company earned ($0.59) EPS.

WVE has been the topic of several research reports. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Wave Life Sciences in a research report on Friday, March 4th. StockNews.com initiated coverage on shares of Wave Life Sciences in a research report on Thursday, March 31st. They set a “hold” rating on the stock.

Shares of Wave Life Sciences stock opened at $1.95 on Friday. Wave Life Sciences has a 1 year low of $1.79 and a 1 year high of $7.55. The company has a market capitalization of $118.65 million, a P/E ratio of -0.82 and a beta of 0.52. The company’s fifty day moving average is $2.25 and its two-hundred day moving average is $3.06.

In other news, CEO Paul Bolno sold 33,150 shares of Wave Life Sciences stock in a transaction dated Wednesday, February 16th. The shares were sold at an average price of $2.32, for a total value of $76,908.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In the last ninety days, insiders sold 63,080 shares of company stock worth $146,152. Insiders own 28.40% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in WVE. BNP Paribas Arbitrage SA boosted its holdings in Wave Life Sciences by 309.8% during the third quarter. BNP Paribas Arbitrage SA now owns 7,396 shares of the company’s stock worth $36,000 after buying an additional 5,591 shares in the last quarter. Point72 Hong Kong Ltd boosted its holdings in Wave Life Sciences by 227.6% during the third quarter. Point72 Hong Kong Ltd now owns 7,843 shares of the company’s stock worth $38,000 after buying an additional 5,449 shares in the last quarter. Citigroup Inc. boosted its holdings in Wave Life Sciences by 69.7% during the third quarter. Citigroup Inc. now owns 8,158 shares of the company’s stock worth $40,000 after buying an additional 3,352 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in Wave Life Sciences by 27,574.0% during the fourth quarter. Wells Fargo & Company MN now owns 20,202 shares of the company’s stock worth $63,000 after buying an additional 20,129 shares in the last quarter. Finally, Invesco Ltd. boosted its holdings in Wave Life Sciences by 23.9% during the third quarter. Invesco Ltd. now owns 15,551 shares of the company’s stock worth $76,000 after buying an additional 3,004 shares in the last quarter. 71.42% of the stock is currently owned by hedge funds and other institutional investors.

Wave Life Sciences Company Profile (Get Rating)

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression.

Further Reading

Get a free copy of the Zacks research report on Wave Life Sciences (WVE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.